New dosing strategy aims to make liver cancer drug easier to tolerate
NCT ID NCT05622136
First seen Mar 27, 2026 · Last updated May 03, 2026 · Updated 6 times
Summary
This study tests a gradual dose increase of the drug regorafenib in 28 adults with advanced liver cancer who have already tried other treatments. The goal is to see if starting at a lower dose and slowly raising it helps patients handle the drug better and complete more cycles of therapy. Researchers will also track quality of life, tumor response, and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICESP - Instituto do Câncer do Estado de São Paulo
São Paulo, São Paulo, 01246-000, Brazil
Conditions
Explore the condition pages connected to this study.